Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

palbociclib 2duvelisib 2berzosertib 2Fulvestrant 2Everolimus 2volagidemab 1serabelisib 1ribociclib 1pembrolizumab 1olaparib 1obinutuzumab 1lorlatinib 1gedatolisib 1encorafenib 1cobimetinib 1chiauranib 1capivasertib 1binimetinib 1Topotecan 1Radiotherapy 1Panobinostat 1PX-866 1NVP-BKM120 1Letrozole 1Cetuximab 1CYH33 1BAY 1895344 1AZD1390 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Hereditary Sensory and Autonomic Neuropathies × berzosertib × Clear all
NCT03309150 2024-11-29

ATRi Transition Rollover Study

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
1 enrolled 4 charts

Hereditary Sensory and Autonomic Neuropathies

NCT05246111 2024-11-22

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Completed
6 enrolled 30 charts

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡